Antibe Therapeutics Announces Results of 2021 Annual Meeting

Rhea-AI Summary

Antibe Therapeutics Inc. (OTCQX: ATBPF) announced successful resolutions during its annual shareholder meeting, with all proposed directors elected. The results include:

• Walt Macnee: 86.88% approval
• Roderick Flower: 86.15% approval
• Robert Hoffman: 87.49% approval
• Amal Khouri: 86.91% approval
• Dan Legault: 71.86% approval
• Jennifer McNealey: 77.66% approval
• John L. Wallace: 73.35% approval
• Yung Wu: 86.73% approval

Voting results are filed on SEDAR, reinforcing Antibe's commitment to advancing its hydrogen sulfide platform for safer therapeutics.

Positive

• All management resolutions were approved during the annual meeting.
• High approval rates for elected directors, indicating strong shareholder support.

Negative

• Dan Legault received the lowest approval rate at 71.86%, which may raise concerns about his leadership.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All resolutions outlined in the management information circular were approved. Detailed results for the election of directors are provided below:

	Director Nominee			Outcome			% For			% Withheld
	Walt Macnee			Elected			86.88%			13.12%
	Roderick Flower			Elected			86.15%			13.85%
	Robert Hoffman			Elected			87.49%			12.51%
	Amal Khouri			Elected			86.91%			13.09%
	Dan Legault			Elected			71.86%			28.14%
	Jennifer McNealey			Elected			77.66%			22.34%
	John L. Wallace			Elected			73.35%			26.65%
	Yung Wu			Elected			86.73%			13.27%

Voting results on all matters voted on at the Meeting have been filed on SEDAR.

About Antibe Therapeutics Inc.

Antibe is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to address inflammation arising from a wide range of medical conditions. The Company’s current pipeline includes three assets that seek to overcome the gastrointestinal (“GI”) ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (“NSAIDs”). Antibe’s lead drug, otenaproxesul, is in clinical development for the treatment of osteoarthritis pain. Additional assets under development include a safer alternative to opioids for peri-operative pain, and a GI-sparing alternative to low-dose aspirin. The Company’s next target is inflammatory bowel disease (“IBD”), a condition long in need of safer, more effective therapies. Learn more at antibethera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210819005780/en/

FAQ

What were the outcomes of Antibe Therapeutics Inc.'s annual meeting of shareholders?

All resolutions proposed by management were approved, including the election of directors.

Who were elected as directors in Antibe's recent shareholder meeting?

Walt Macnee, Roderick Flower, Robert Hoffman, Amal Khouri, Dan Legault, Jennifer McNealey, John L. Wallace, and Yung Wu were elected.

What is the stock symbol for Antibe Therapeutics?

The stock symbol for Antibe Therapeutics is ATBPF.

What platform does Antibe Therapeutics leverage for drug development?

Antibe leverages a proprietary hydrogen sulfide platform to develop safer medicines.

Where can I find the voting results from Antibe's annual meeting?

The voting results have been filed on SEDAR.